COVID-19 drug development : : recent advances, new perspectives and applications / / Arli Aditya Parikesit, editor.

COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Place / Publishing House:London : : IntechOpen,, 2022.
Year of Publication:2022
Language:English
Physical Description:1 online resource (166 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02571nam a2200313 i 4500
001 993603605404498
005 20230625162538.0
006 m o d
007 cr |||||||||||
008 230625s2022 enk ob 000 0 eng d
024 7 |a 10.5772/intechopen.100969  |2 doi 
035 |a (CKB)5580000000514513 
035 |a (NjHacI)995580000000514513 
035 |a (EXLCZ)995580000000514513 
040 |a NjHacI  |b eng  |e rda  |c NjHacl 
050 4 |a RM301.25  |b .C685 2022 
082 0 4 |a 615.19  |2 23 
245 0 0 |a COVID-19 drug development :  |b recent advances, new perspectives and applications /  |c Arli Aditya Parikesit, editor. 
264 1 |a London :  |b IntechOpen,  |c 2022. 
300 |a 1 online resource (166 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 |a Description based on publisher supplied metadata and other sources. 
520 |a COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in light of these advances in life sciences. 
504 |a Includes bibliographical references. 
505 0 |a 1. Introductory Chapter: Current Perspective of COVID-19 Drugs 22 -- 2. Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 -- 3. Baricitinib in the Treatment of COVID-19 53 -- 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 -- 5. Treatments for the Infection by SARS-CoV-2 49 -- 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 -- 7. COVID-19: From Pathophysiology to Treatment 35 -- 8. COVID-19 Drug Development: Role of Drug Repurposing 16. 
650 0 |a Drug development. 
776 |z 1-80356-991-3 
700 1 |a Parikesit, Arli Aditya,  |e editor. 
906 |a BOOK 
ADM |b 2023-07-06 03:15:04 Europe/Vienna  |f system  |c marc21  |a 2023-02-11 21:29:23 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5343039350004498&Force_direct=true  |Z 5343039350004498  |b Available  |8 5343039350004498